Harrow, Inc. Unrecognized Tax Benefits that Would Impact Effective Tax Rate
Harrow, Inc. (HROW) had Unrecognized Tax Benefits that Would Impact Effective Tax Rate of $307.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate · last filed 2026-03-02
- 2025-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $307.00K.
- 2024-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $2.86M.
- 2023-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $2.82M; Unrecognized Tax Benefits that Would Impact Effective Tax Rate as first filed $2.85M.
| Period end | Unrecognized Tax Benefits that Would Impact Effective Tax Rate | Unrecognized Tax Benefits that Would Impact Effective Tax Rate as first filed |
|---|---|---|
| 2025-12-31 | $307.00K 10-K · filed 2026-03-02 | |
| 2024-12-31 | $2.86M 10-K · filed 2026-03-02 | |
| 2023-12-31 | $2.82M 10-K · filed 2025-03-27 | $2.85M 10-K · filed 2024-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |